What is Sacituzumab govitecan?

Sacituzumab govitecan, branded as Trodelvy, is a Trop-2-directed antibody and topoisomerase inhibitor drug conjugate for the treatment of metastatic triple-negative breast cancer and metastatic urothelial carcinoma. It is considered a potential treatment option and has been approved for marketing in some countries.

Sacituzumab govitecan in clinical models is a Trop-2-directed antibody-drug conjugate and a humanized antibody that recognizes Trop-2. The small molecule SN-38 is a topoisomerase I inhibitor covalently linked to the antibody through a linker. Pharmacological data indicate that gosatuzumab binds to Trop-2-expressing cancer cells and is internalized via hydrolysis of the linker with subsequent release of SN-38. SN-38 interacts with topoisomerase I and prevents the religation of topoisomerase I-induced single-strand breaks. The resulting DNA damage leads to apoptosis and cell death. Gosatuzumab reduces tumor growth in a triple-negative mouse xenograft model of cancer.

Gosatuzumab The original drug has been launched in China, but it has not yet been included in the medical insurance. The price of a 100mg bottle may be around 10,000 yuan, which is relatively expensive. Gosatuzumab Original drug marketed overseas has three versions: European version, American version, and Singapore version. SpecificationsThe price of each 100 mg bottle may be around RMB 10,000-35,000 (the price may fluctuate due to exchange rates). The ingredients of gosatuzumab sold domestically and abroad are basically the same. There is currently no generic version of gosatuzumab available on the market. For specific prices and drug information, please consult your medical consultant.